The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Promising Treatment for Eosinophilic Granulomatosis with Polyangiitis

Promising Treatment for Eosinophilic Granulomatosis with Polyangiitis

June 20, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Although eosinophilic granulomatosis with polyangiitis can affect many organ systems, it most commonly damages the lungs. Many patients present with asthma symptoms and, occasionally, pulmonary infiltrates. Additionally, patients with eosinophilic granulomatosis with polyangiitis have a predominance of eosinophils in their peripheral blood and tissues. This finding has led researchers to suggest that eosinophils play an important role in disease pathogenesis.

You Might Also Like
  • The Latest on Eosinophilic Granulomatosis with Polyangiitis
  • Granulomatosis with Polyangiitis: A Case Review
  • Granulomatosis with Polyangiitis Rates & Outcomes
Also By This Author
  • Osteoporosis Experts Discuss Bisphosphonates, Chronic Kidney Disease

Recently, Michael E. Wechsler, MD, a pulmonologist at National Jewish Health in Denver, and colleagues reported that patients with eosinophilic granulomatosis with polyangiitis who are treated with the anti-interleukin 5 monoclonal antibody, mepolizumab, experience significantly more weeks of remission than patients receiving placebo. The investigators published the results of their randomized, double-blind, placebo-controlled trial in the May 18 issue of the New England Journal of Medicine.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study included 136 patients with the rare condition of relapsing or refractory eosinophilic granulomatosis with polyangiitis. All of the patients were receiving standard-of-care therapy, which meant the population was representative of patients with the disease who are treated with glucocorticoids (at least 7.5 mg prednisone per day) with or without additional immunosuppressive therapy. The clinical trial enrolled patients at centers of expertise that were equipped to document glucocorticoid use throughout the trial. The study also had two primary endpoints: accrued weeks of disease remission and the proportion of patients who were in remission at Weeks 36 and 48. The investigators used the Birmingham Vasculitis Activity Score (BVAS) to characterize disease activity and outcomes.

“The results of our trial show an advance for patients with this rare disease,” write the authors in their paper. “Approximately half the participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who were treated with mepolizumab had clinically relevant improvements in the rates of protocol-defined remission and relapse, which allowed for reduced glucocorticoid use. Although 81% of the participants in the placebo group had no accrued weeks of remission, 47% of those in the mepolizumab group did not have protocol-defined remission, either, which suggests that not all patients will have the same benefit.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In other words, 28% of patients in the treatment group experienced ≥24 weeks of accrued remission, whereas only 3% of patients in the control group experienced ≥24 weeks of accrued remission. In addition, at both Weeks 36 and 48, many more patients in the treatment group than placebo group were in remission (32% vs. 3% at both weeks). The study did not reveal any new safety signals from mepolizumab.

Pages: 1 2 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: Eosinophilic Granulomatosis, Polyangiitis

You Might Also Like:
  • The Latest on Eosinophilic Granulomatosis with Polyangiitis
  • Granulomatosis with Polyangiitis: A Case Review
  • Granulomatosis with Polyangiitis Rates & Outcomes
  • The Classification & Diagnosis of Granulomatosis with Polyangiitis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)